UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2803-2811

2015

Link zum Volltext

Verfügbarkeit prüfen

How and when I do allogeneic transplant in CLL

Blood, 2018-07, Vol.132 (1), p.31-39

Gribben, John G.

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting the methylome to improve CLL outcome

Blood, 2023-07, Vol.142 (1), p.4

Gribben, John G

2023

Link zum Volltext

Verfügbarkeit prüfen

How I treat CLL up front

Blood, 2010-01, Vol.115 (2), p.187-197

Gribben, John G.

2010

Link zum Volltext

Verfügbarkeit prüfen

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia

British journal of haematology, 2020-03, Vol.188 (6), p.844-851

Gribben, John G.

2020

Link zum Volltext

Verfügbarkeit prüfen

The role of B7 family molecules in hematologic malignancy

Blood, 2013-01, Vol.121 (5), p.734-744

2013

Link zum Volltext

Verfügbarkeit prüfen

To start and stop or just keep going?

Blood, 2021-09, Vol.138 (10), p.819-820

Gribben, John G.

2021

Link zum Volltext

Verfügbarkeit prüfen

Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?

Genomics (San Diego, Calif.), 2014-11, Vol.104 (5), p.352-357

2014

Link zum Volltext

Verfügbarkeit prüfen

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies

Seminars in cancer biology, 2014-02, Vol.24, p.71-81

2014

Link zum Volltext

Verfügbarkeit prüfen

Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?

British journal of haematology, 2020-05, Vol.189 (4), p.603-604

Gribben, John G.

2020

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia

Blood, 2015-07, Vol.126 (2), p.203-211

2015

Link zum Volltext

Verfügbarkeit prüfen

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

Blood, 2012-08, Vol.120 (7), p.1412-1421

2012

Link zum Volltext

Verfügbarkeit prüfen

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice

British journal of haematology, 2018-03, Vol.180 (5), p.666-679

2018

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.43-56

2019

Link zum Volltext

Verfügbarkeit prüfen

Bone marrow niches in haematological malignancies

Nature reviews. Cancer, 2020-05, Vol.20 (5), p.285

2020

Link zum Volltext

Verfügbarkeit prüfen

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

Leukemia, 2018-05, Vol.32 (5), p.1261-1265

2018

Link zum Volltext

Verfügbarkeit prüfen

No longer too exhausted to run

Blood, 2018-08, Vol.132 (5), p.464-465

Gribben, John G.

2018

Link zum Volltext

Verfügbarkeit prüfen

Update on Therapy of Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2011-02, Vol.29 (5), p.544-550

2011

Link zum Volltext

Verfügbarkeit prüfen

The role of BTK inhibitors on the tumor microenvironment in CLL

Leukemia & lymphoma, 2022-07, Vol.63 (9), p.2023-2032

2022

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2722-2729

2019

Link zum Volltext

Verfügbarkeit prüfen

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

Blood, 2013-02, Vol.121 (9), p.1612-1621

2013

Link zum Volltext

Verfügbarkeit prüfen

Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells

PloS one, 2012-02, Vol.7 (2), p.e32584-e32584

2012

Link zum Volltext

Verfügbarkeit prüfen

Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma

Gastroenterology (New York, N.Y. 1943), 2013-11, Vol.145 (5), p.1121-1132

2013

Link zum Volltext

Verfügbarkeit prüfen

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Journal of clinical oncology, 2019-05, Vol.37 (14), p.1188-1199

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 870

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(736)
Mit Volltextzugriff
(797)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(434)
Life Sciences & Biomedicine
(406)
Humans
(396)
Hematology
(270)
Female
(125)
Biological And Medical Sciences
(124)
Male
(124)
Oncology
(122)
Medical Sciences
(115)
Middle Aged
(110)
Adult
(94)
Hematologic And Hematopoietic Diseases
(80)
Animals
(73)
Aged
(72)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(71)
Treatment Outcome
(61)
Prognosis
(57)
Chronic Lymphocytic Leukemia
(52)
Leukemia
(52)
Mice
(51)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(49)

Menü

Weitere Dienste

Einstellungen

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

How and when I do allogeneic transplant in CLL

Targeting the methylome to improve CLL outcome

How I treat CLL up front

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia

The role of B7 family molecules in hematologic malignancy

To start and stop or just keep going?

Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies

Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Bone marrow niches in haematological malignancies

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

No longer too exhausted to run

Update on Therapy of Chronic Lymphocytic Leukemia

The role of BTK inhibitors on the tumor microenvironment in CLL

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Suchergebnisse filtern